Spruce Biosciences, Inc.
A clinical-stage biopharmaceutical company developing drug therapies for rare endocrine (hormone) disorders. Its lead experimental medicine, tildacerfont, is being studied for people living with congenital adrenal hyperplasia, a rare genetic condition that disrupts the body's hormone production. Founded in 2013 and based in South San Francisco, the company went public on the US stock market in 2021.
Granted 18.3K
Granted 5.5K
Bought 256 · Sold 257
Bought 256 · Sold 257
Granted 1.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Szwarcberg Javier B.CHIEF EXECUTIVE OFFICER, Director · 11 transactions | -95.6% | 19.0K | 18.3K | — | — |
| Gharib Samir M.PRESIDENT AND CFO · 10 transactions | -97.6% | 8.3K | 5.5K | — | — |
| Parkman Healthcare Partners LLC10% owner · 3 transactions | — | 2.4K | — | 256 | 257 |
| Martinez Gregory +1 co-filer10% owner · 3 transactions | — | 2.1K | — | 256 | 257 |
| Ways Douglas KirkInterim Chief Medical Officer, Director · 1 transaction | — | 1.3K | 1.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -2 shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.